Aktienanalyse zu STERIS plc (STE)STESTERIS plc

STERIS Plc is a provider of products and services that support patient care with an emphasis on infection prevention. Its segments include Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. Its Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. AST segment supports medical device and pharmaceutical manufacturers through a global network of contract sterilization and laboratory testing facilities, and integrated sterilization equipment and control systems. Its Life Sciences segment provides a comprehensive offering of products and services designed to support biopharmaceutical and medical device manufacturing facilities, particularly those focused on aseptic manufacturing. Its portfolio includes a full suite of consumable products, equipment maintenance, specialty services, and capital equipment. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUP industry).

Steris plc is a good buy right now due to its current price of $214.4, which is below analyst targets of $275 and $269, indicating significant upside potential. The company reported a strong Q1 2027 EPS of $2.59, exceeding expectations by $0.10, and a revenue growth of 7.9% year-over-year, showcasing solid market demand. However, the RSI is at 70.106, indicating it may be overbought, which is a risk to consider.

8 analysts cover STE: 6 rate it Buy, 2 Hold and 0 Sell.